Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.78 |
| ▸ | LCK | P06239 | 1/20 | 0.78 |
| ▸ | FYN | P06241 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL27465824 | 1.00 | FFAR3 (0.78) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL28054628 | 1.00 | FFAR3 (0.78) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL1761127 | 1.00 | FFAR3 (0.78) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL30925595 | 1.00 | FFAR3 (0.78) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL10625833 | 0.95 | FFAR3 (0.70) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL4654686 | 0.95 | FFAR3 (0.70) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL3673826 | 0.95 | FFAR3 (0.70) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL20972992 | 0.95 | FFAR3 (0.70) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL11667036 | 0.95 | FFAR3 (0.70) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL27480367 | 0.95 | FFAR3 (0.70) | FFAR3LCKFYNLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117225384-B | Composite material capable of efficiently adsorbing formaldehyde and noble metal as well as preparation method and application thereof | 天津得瑞丰凯新材料科技有限公司 | 2024-02-09 | — | — | CN | claimed |
| CN-117225384-A | Composite material capable of efficiently adsorbing formaldehyde and noble metal as well as preparation method and application thereof | 天津得瑞丰凯新材料科技有限公司 | 2023-12-15 | — | — | CN | claimed |
| CN-111393660-A | Nickel metal coordination polymer and preparation method and application thereof | 延安大学 | 2020-07-10 | — | — | CN | claimed |
| CN-111205473-A | Zinc metal coordination polymer and preparation method and application thereof | 延安大学 | 2020-05-29 | — | — | CN | claimed |
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | GLENMARK SPECIALITY S.A. (CH) | 2026-03-17 | — | — | US | disclosed |
| US-12577217-B2 | 15-PGDH inhibitor | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2026-03-17 | — | — | US | disclosed |
| CN-120189526-A | Hoberthidiene antibody-drug conjugates and methods of use | 卫材R&D管理有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-113271981-B | Hoberthidiene antibody-drug conjugates and methods of use | 卫材R&D管理有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119462483-A | Long-acting flame-retardant anti-aging auxiliary agent and preparation method and application thereof | 宿迁联宏新材料有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240325426-A1 | POLYNUCLEOTIDE AND PHARMACEUTICAL COMPOSITION | KYOWA KIRIN CO., LTD. (JP) | 2024-10-03 | — | — | US | disclosed |
| EP-4367123-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | Glenmark Specialty S.A. (CH) | 2024-05-15 | — | — | EP | disclosed |
| EP-4365288-A1 | POLYNUCLEOTIDE AND MEDICINAL COMPOSITION | Kyowa Kirin Co., Ltd. (JP) | 2024-05-08 | — | — | EP | disclosed |
| CN-113774522-A | High-elongation high-strength polyurethane elastic fiber and preparation method thereof | 华峰化学股份有限公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-112391632-A | Corrosion inhibitor, preparation method thereof and method for inhibiting naphthenic acid corrosion in oil product | 广昌达新材料技术服务（深圳）股份有限公司 | 2021-02-23 | — | — | CN | disclosed |
| CN-106674130-B | Bipyrimidinediamine and preparation method thereof | 江西师范大学 | 2020-07-31 | — | — | CN | disclosed |
| CN-111393660-A | Nickel metal coordination polymer and preparation method and application thereof | 延安大学 | 2020-07-10 | — | — | CN | disclosed |
| CN-111205473-A | Zinc metal coordination polymer and preparation method and application thereof | 延安大学 | 2020-05-29 | — | — | CN | disclosed |
| CN-106537564-B | Sealing composition and method for manufacturing semiconductor device | 三井化学株式会社 | 2020-02-21 | — | — | CN | disclosed |
| EP-3540008-A1 | RESIN COMPOSITION AND MULTILAYERED STRUCTURE USING SAME | Mitsubishi Chemical Corporation (JP) | 2019-09-18 | — | — | EP | disclosed |
| US-20190256700-A1 | RESIN COMPOSITION AND MULTILAYERED STRUCTURE USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577217-B2 | 15-PGDH inhibitor | PTGDR, ADH1A, ADRA1A | FFAR3 594/4885LCK 4885/4885FYN 4709/4885 |
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | PTK2B, MAP3K10, MAP3K20 | FFAR3 2356/4885LCK 37/4885FYN 26/4885 |
| US-20240325426-A1 | POLYNUCLEOTIDE AND PHARMACEUTICAL COMPOSITION | RNGTT, RNMT, NT5C | FFAR3 1541/4885LCK 2581/4885FYN 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.